Isto Biologics Debuts Fibrant Liberty: A Leap In Bone Grafting Technology

Isto Biologics, renowned for its leadership in regenerative and autologous therapies, has announced the introduction of Fibrant Liberty™, marking a significant step forward within its Fibrant line of allograft solutions. This launch heralds Fibrant Liberty as the inaugural product entirely developed in-house at Isto Biologics, showcasing an evolution in bone grafting technology with its advanced composition and swift hydration features.

Fibrant Liberty emerges as a dry allograft blend that combines durable cortical fibers with mineralized cortical cancellous chips. This innovative mixture, upon hydration, transforms into a malleable substance that can be customized to suit the specific requirements of various surgical interventions. The product's enhanced fibers™ guarantee exceptional handling and form a complex network that inhibits graft migration while maintaining structural integrity. Moreover, Fibrant Liberty incorporates a unique open-bore syringe design facilitating immediate and uniform hydration with the surgeon’s chosen fluid. Importantly, the product maintains the purity of the graft by excluding additives that could dilute bone content, thus promoting optimal bone growth. The addition of cortical cancellous chips further benefits postoperative assessment and delivers compression resistance to preserve the volume of the fusion mass.

Dr. Nelson Scarborough, the chief developer of the graft, emphasized the strategic design behind Fibrant Liberty. He stated, "Fibrant Liberty effectively removes the uncertainty from bone grafting procedures. It is designed for rapid hydration with BMA to provide a comprehensive graft comprising cells, signal, and scaffold. This solution's visible and robust design empowers surgeons to perform fusions with confidence."

Following its acquisition of TheraCell and their TheraFuze DBF® line in 2022, Isto Biologics has concentrated on refining the newly envisioned Fibrant line with an array of effective allograft solutions. Fibrant Liberty epitomizes the company’s commitment to innovation and its dedication to delivering superior quality products that expedite patient recovery.

Don Brown, CEO of Isto Biologics, expressed his enthusiasm about the new launch, stating, "We are excited to introduce Fibrant Liberty as the newest member of our Fibrant line. This launch highlights our ongoing commitment to developing allograft solutions that significantly improve patient outcomes and assist healthcare professionals in their clinical practice."

About Isto Biologics: Isto Biologics stands as a premier biologics and cellular therapy enterprise. It is dedicated to Helping Patients Heal Faster™ through cutting-edge solutions for bone regeneration and cell-based therapies. Isto takes pride in offering the most comprehensive and innovative biologics products available. Since its foundation, Isto has expanded its portfolio to include a wide range of bone grafting solutions across all categories of bone grafts; InQu® Bone Graft Extender & Substitute; Influx™ Advanced Allograft Technology featuring Fibrant™ Functional Allograft Constructs, SPARC Integrative Bone Matrix, and ProteiOS Allograft-Derived Proteins.